Boston Scientific Expands Board with Two New Members

Marlborough, Mass-based medical device company Boston Scientific Corp. has elected Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015. Two current members of the board, Uwe E. Reinhardt, Ph.D., and Bruce L. Byrnes, will not stand for re-election at the company’s annual meeting of stockholders in May 2015.

Charles J. Dockendorff was formerly the executive vice president and chief financial officer of Covidien plc. He currently serves on the board of directors of Haemonetics Corporation and Keysight Technologies. He received his B.A. in business administration and accounting from the University of Massachusetts at Amherst and received his master of science in finance from Bentley College.

Stephen P. MacMillan is currently the president and CEO of Hologic, a global healthcare and diagnostics company. Previously, MacMillan served as president and CEO of Stryker Corporation. He currently serves on the board of directors of Alere Inc. MacMillan received a Bachelor of Arts degree in economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program.

“We are thankful for the guidance and years of dedicated service that Dr. Reinhardt and Mr. Byrnes contributed to Boston Scientific, and we are pleased to welcome Mr. Dockendorff and Mr. MacMillan to our board,” said Board Chairman Pete Nicholas. “Their extensive experience and management insights will be valuable additions as we continue to deliver meaningful innovation to address the unmet needs of patients around the world.”